Loading...
XNASSLGL
Market cap23mUSD
Dec 24, Last price  
0.86USD
1D
-48.17%
1Q
21.44%
IPO
-93.11%
Name

Sol Gel Technologies Ltd

Chart & Performance

D1W1MN
XNAS:SLGL chart
P/E
—
P/S
15.41
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
8.68%
Rev. gr., 5y
64.50%
Revenues
2m
-59.98%
000174,000129,00022,904,0008,771,00031,272,0003,883,0001,554,000
Net income
-27m
L+100.25%
-4,848,000-9,660,000-20,771,000-31,568,000-32,203,000-24,609,000-27,401,0004,358,000-13,602,000-27,238,000
CFO
-18m
L+86.95%
-4,830,000-8,044,000-18,495,000-24,089,000-23,467,000-22,500,000-25,241,000-7,691,000-9,484,000-17,730,000
Earnings
Mar 11, 2025

Profile

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
URL
http://www.sol-gel.com
IPO date
Feb 01, 2018
Employees
55
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,554
-59.98%
3,883
-87.58%
31,272
256.54%
Cost of revenue
54,455
32,809
49,213
Unusual Expense (Income)
NOPBT
(52,901)
(28,926)
(17,941)
NOPBT Margin
Operating Taxes
(1,321)
(1,137)
Tax Rate
NOPAT
(52,901)
(27,605)
(16,804)
Net income
(27,238)
100.25%
(13,602)
-412.12%
4,358
-115.90%
Dividends
Dividend yield
Proceeds from repurchase of equity
21,542
15
505
BB yield
-71.97%
-0.01%
-0.29%
Debt
Debt current
447
718
781
Long-term debt
2,859
826
2,401
Deferred revenue
Other long-term liabilities
915
1,032
1,093
Net debt
(35,974)
(33,370)
(48,760)
Cash flow
Cash from operating activities
(17,730)
(9,484)
(7,691)
CAPEX
(134)
(171)
(143)
Cash from investing activities
(9,742)
1,699
19,872
Cash from financing activities
21,810
15
837
FCF
(46,702)
(30,453)
(18,597)
Balance
Cash
37,996
33,626
43,242
Long term investments
1,284
1,288
8,700
Excess cash
39,202
34,720
50,378
Stockholders' equity
(219,529)
(192,427)
(177,504)
Invested Capital
260,741
236,444
235,782
ROIC
ROCE
EV
Common stock shares outstanding
27,087
23,129
23,566
Price
1.11
-75.77%
4.56
-38.38%
7.40
-24.41%
Market cap
29,931
-71.62%
105,465
-39.52%
174,390
-21.09%
EV
(6,043)
72,095
125,630
EBITDA
(52,559)
(28,364)
(17,061)
EV/EBITDA
0.11
Interest
1,321
Interest/NOPBT